Advertisement

Comment on “Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies”

  • 9 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Masson W, Rossi E, Mora-Crespo LM, Cornejo-Pena G, Pessio C, Gago M et al (2019) Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies. Clin Rheumatol:1–8. https://doi.org/10.1007/s10067-019-04856-z

  2. 2.

    Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, Ozturk C, Arslan S, Sakız D, Sahin M, Kucuk A (2016) Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology 67:749–755

  3. 3.

    Uslu AU, Kucuk A, Icli A, Cure E, Sakiz D, Arslan S et al (2017) Plasma atherogenic index is an independent indicator of subclinical atherosclerosis in systemic lupus erythematosus. Eurasian J Med 49:193–197

  4. 4.

    Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group (2013) KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Inter 3:259–305

  5. 5.

    Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377:2181–2192

  6. 6.

    Roy R, Ajithan A, Joseph A, Mateti UV, K S (2019) Statin-induced new onset of diabetes in dyslipidemic patients: a retrospective study. Postgrad Med. https://doi.org/10.1080/00325481.2019.1643636

  7. 7.

    Sinicato NA, Postal M, de Oliveira PK, Rittner L, Marini R, Appenzeller S (2017) Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus. Clin Rheumatol 36:1527–1535

  8. 8.

    Cho Y, Lee H, Park HK, Choe EY, Wang HJ, Kim RH et al (2019) Differential diabetogenic effect of pitavastatin and rosuvastatin, in vitro and in vivo. J Atheroscler Thromb. https://doi.org/10.5551/jat.50039

  9. 9.

    Chen LW, Lin CS, Tsai MC, Shih SF, Lim ZW, Chen SJ et al (2019) Pitavastatin exerts potent anti-inflammatory and immunomodulatory effects via the suppression of AP-1 signal transduction in human T cells. Int J Mol Sci. https://doi.org/10.3390/ijms20143534

  10. 10.

    Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM (2019) An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother 20:103–113

  11. 11.

    https://www.drugs.com/drug-interactions/pitavastatin,nikita.html

  12. 12.

    Hartman O, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J (2017) Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother 3:92–97

  13. 13.

    Pareek A, Yeole PG, Tenpe CR, Chandurkar N, Payghan R (2009) Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol 41:125–128

Download references

Author information

Correspondence to Erkan Cure.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cure, E., Cumhur Cure, M. Comment on “Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies”. Clin Rheumatol (2020). https://doi.org/10.1007/s10067-019-04897-4

Download citation